# Spyryx Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spyryx-biosciences

- Industry: Pharmaceuticals
- Headquarters: Durham, US
- Website: www.spyryxbio.com
- Total disclosed funding: $18M
- Latest round: Series A (Apr 24, 2015)
- Investors on record: 3

## About

Spyryx Biosciences is dedicated to developing innovative therapeutics for obstructive lung diseases like Cystic Fibrosis and COPD. Their lead product, SPX-101, targets epithelial sodium channels to improve lung function.Founded in 2013 in Durham, US, Spyryx Biosciences focuses on creating therapies for lung diseases. The company has completed a total of 4 deals, with the most recent being a Venture Debt round in October 2018 that raised USD 5.93 mn, bringing total funding raised to USD 18.17 mn.Spyryx Biosciences specializes in developing innovative therapeutics for obstructive lung diseases, primarily targeting Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD). Their lead investigational product, SPX-101, is an inhaled peptide designed to enhance mucociliary clearance by targeting epithelial sodium channels (ENaC), addressing dehydration-induced lung disease. SPX-101 has progressed through Phase 1 studies and is currently undergoing Phase 2 trials in international markets, including Canada, the UK, France, and Portugal, focusing on adult patients diagnosed with CF.Spyryx Biosciences generates revenue through the clinical development and commercialization of its therapeutic products, mainly SPX-101. As clinical trials advance, potential revenue may derive from partnerships with healthcare institutions and agreements with pharmaceutical distributors. The financial structure will support various pricing plans based on the therapeutic benefits of SPX-101, with market uptake driven by evidence-based efficacy and safety.Spyryx Biosciences plans to utilize the USD 5.93 mn raised in the latest funding round to support the ongoing clinical trials of SPX-101 and pursue additional product development. The company aims to expand its reach into new geographical markets, focusing on regions such as Canada and Europe by the end of 2021. Additionally, Spyryx is exploring the development of new products that align with their mission to treat obstructive lung diseases, ensuring a strategic approach to growth.

## Funding rounds

- Series A, Apr 24, 2015, $18M — Canaan Partners, Hatteras Venture Partners, 5AM Ventures

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A